SAN CARLOS, CA — Sift Biosciences is proud to announce that it has been selected as one of ten startups joining the second cohort of Plug and Play’s Seattle-based accelerator program. The 12-week program brings together early-stage companies across enterprise software, biotech, cybersecurity, and health tech, providing access to mentorship, corporate introductions, workshops, and networking opportunities.
Programming runs from late September through mid-December and takes place primarily at Plug and Play’s Seattle office inside the University of Washington’s CoMotion Labs.
“Plug and Play has built one of the most extensive innovation networks in the world, and we’re excited to be part of their second Seattle cohort,” said Dr. Yue Clare Lou, Co-Founder and CEO of Sift Biosciences. “The Pacific Northwest is home to deep expertise in both biotech and applied AI — two communities at the heart of what we’re building. We’re looking forward to the connections, mentorship, and partnerships this program will help us forge as we advance the SIFT™ platform.”
“The fact that these founders — both from within the Pacific Northwest and beyond — have chosen Seattle as a key market for commercialization speaks volumes about the region’s strength as a hub for innovation and scale. We’re proud to play a part in their growth stories,” said Jack Callaghan, Director of Plug and Play Seattle.
Read the full announcement on GeekWire.
About Sift Biosciences
Sift Biosciences is a preclinical immunotherapy company developing immunomodulators that harness pre-existing memory T-cells to treat immune dysfunctions. Founded in 2024 as a UC Berkeley spin-out, Sift integrates AI and high-throughput T-cell screening to mine billions of microbial proteins for motifs that activate antimicrobial memory T-cells and steer them toward tumor antigens, autoantigens, and other disease-relevant targets. The company’s initial focus is on oncology, with expanding pipelines in autoimmunity and immunosenescence.